2 results match your criteria: "Oregon Health & Science University Hospital[Affiliation]"
Article Synopsis
- Aficamten is a new drug that helps reduce heart issues in patients with obstructive hypertrophic cardiomyopathy by targeting heart muscle contractility and maintaining safe blood flow levels.
- * In a clinical trial involving 282 patients, those receiving aficamten were able to maintain effective heart function with minimal side effects, including a stable reduction in heart muscle contraction without significant adverse events.
- * The findings suggest that using a tailored dosing strategy for aficamten is effective and safe, improving cardiovascular health without worsening conditions like heart failure.
Article Synopsis
- * A study conducted from April 3 to June 19, 2020, found that among 3,248 frontline HCP, 6% tested positive for SARS-CoV-2 antibodies, with significant variability in infection rates across hospitals.
- * Many infected HCP were asymptomatic or did not recognize their infection, highlighting the need for enhanced screening and the consistent use of personal protective equipment (PPE) to minimize virus transmission in healthcare settings.